Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand.

ABSTRACT:

Background

Previous studies showed that Favipiravir, a selective viral ribonucleic acid dependent-ribonucleic acid polymerase inhibitor, exhibited a trend of clinical improvement within 14 days and promoted viral clearance by day 7, without reduction of mortality rate in COVID-19.

Methods

During the COVID-19 pandemic, Department of Medical Services (Thailand) formulated National Clinical Treatment Guidelines for COVID-19 and approved Favipiravir to eight medical centres. After treatment with Favipiravir monotherapy, we compared real-world data analysis to supportive treatment without antiviral agents.

Findings

We analysed 12,888 COVID-19 patients between June 1, 2021, and July 31, 2021. This group study excluded 66 asymptomatic and 4634 COVID-19 patients treated with

SUBMITTER: Srisubat A 

PROVIDER: S-EPMC9902286 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature